Dr. Lheureux is a Medical Oncologist, Clinician Investigator, Site Lead of Gynecology Oncology and co-director of the Beyond Chemotherapy Program at Princess Margaret Cancer Centre. She holds the Westaway Chair in Ovarian Cancer Research and is an Associate Professor of Faculty of Medicine at the University of Toronto. Her clinical and academic interests are focused in gynecologic cancers and early drug development with an emphasis on translational research and have garnered two ASCO Merit awards. She received the 2019 Career Development Award from the American Society of Clinical Oncology (ASCO) and the 2021 Young Investigator Award from University of Toronto Division of Medical Oncology. Internationally, she is co-Chair of the Translational Research Committee and Director representing Princess Margaret Consortium at the international Gynecologic Cancer InterGroup (GCIG). She is also a member of the Gynecologic Cancer Steering Committees at the US National Cancer Institute. In the last five years, she has >60 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians, Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology and Gynecology Oncology. She is principal investigator or co-principal investigator of various clinical trials and holds funding from the Canadian Cancer Society Research Institute, Conquer Cancer Foundation/American Society for Clinical Oncology, Ontario Institute for Cancer Research, Ovarian Cancer Canada and Terry Fox Research Institute.
Dr. Lheureux's clinical and research interests are on integrating translational research in early phase gynecologic cancer clinical trials and incorporating these findings into the clinic in a timely manner. She is a principal investigator or sub-investigator for numerous clinical trials in gynecologic cancers at Princess Margaret, a member of the Gynecologic Cancer InterGroup, and co-investigator on several large scale programs supported by the Canadian Cancer Society Research Institute and the Ontario Institute for Cancer Research.